this May. “And so, we're trying to automate out some of the steps that might lead to bottlenecks and longer timelines in both construct design for manufacturing and data analysis.”
“The way that we like to think about Form Bio is that it's a platform to enable synthetic biology,” explains Stearn. “Typical synbio organizations have heavy R&D investment on the science side of things, but the data science side might be under-resourced. Our platform is a one-stop shop for all things data management, visualization, analysis, workflows, and collaboration.”
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: